Lumosa Therapeutics

Biotechnology Research • 4th Floor, No. 3-2, Taiwan, Province of China • 21-50 Employees

Company overview

Headquarters	4th Floor, No. 3-2, Park Street, Nangang District, Taipei, 11503, TW
Website	lumosa.com.tw
NAICS	541714
SIC	283
Keywords	Pain Management, Oncology, Exosomes, Neurological Diseases, Acute Ischemic Stroke, Uremic Pruritus
Founded	2001
Employees	21-50
Socials

Key Contacts at Lumosa Therapeutics

Clara Chang

Director, Business Development

June Kuo

Senior Director Of Clinical Division

Nai-Jing Liu

Seninor Director/New Drug Development Division

莊欣怡 Judy Juang

Director, Project Management & Regulatory Affairs

Lumosa Therapeutics Email Formats

Lumosa Therapeutics uses 2 email formats. The most common is {first initial}_{last name} (e.g., j_doe@lumosa.com.tw), used 50% of the time.

Format	Example	Percentage
{first initial}_{last name}	j_doe@lumosa.com.tw	50%
{first name}_{last name}	john_doe@lumosa.com.tw	50%

About Lumosa Therapeutics

Lumosa Therapeutics, a public traded company in Taipei Exchange (6535.TWO), is dedicated to the development of innovative new drugs for the treatment of neurological and oncological diseases of unmet medical needs. The company is actively engaged in scientific in-licensing and new drug development under the “reSEARCH and DEVELOPMENT” model. This model is executed by a highly capable and experienced cross-functional teams of translational research, CMC, preclinical, clinical development, project management, regulatory affairs, intellectual property and business development experts. Current products/pipeline include Naldebain®, a long long-acting analgesic injection, launched in Taiwan in 2017, Singapore in 2020, Thailand in 2021, Malaysia in 2022, and Ukraine and Brunei in 2023; LT3001, an NCE for the treatment of acute ischemic stroke currently under phase II clinical trial in the US, EU, China and Taiwan; LT2003, tumor-targeting enzyme prodrug; LT5001, a novel topical drug for uremic pruritus; and LT6001, a novel exosome for treating nerve damages. The photo of Chingshui Cliff is used for the home page. The coastal cliff, located in Taroko National Park, averages 800 meters above sea level. The geo-formation of the cliff involves three continental plates: the Eurasian Plate, the Philippine Sea Plate, and the Pacific Plate. The collision of these three plates is what has led to the formation of the cliff. The sudden rise and majestic scene of the Chingshui Cliff represent our company's strive to achieve excellence and stand out in our industry.

Lumosa Therapeutics revenue & valuation

Annual revenue	$3,507,755
Revenue per employee	$86,000
Estimated valuation?This valuation is estimated based on industry average for the Biotechnology Research industry and current estimated revenues	$11,300,000
Total funding	No funding

Employees by Management Level

Total employees: 21-50

Seniority

Employees

Manager

Entry

Director

Employees by Department

Lumosa Therapeutics has 13 employees across 5 departments.

Departments

Number of employees

Funding Data

Lumosa Therapeutics has never raised funding before.

Lumosa Therapeutics Tech Stack

Discover the technologies and tools that power Lumosa Therapeutics's digital infrastructure, from frameworks to analytics platforms.

Nginx

Reverse proxies

Microsoft 365

Frequently asked questions

Lumosa Therapeutics is located in 4th Floor, No. 3-2, TW.

Lumosa Therapeutics was founded in 2001, making it 25 years old. The company has established itself as a significant player in its industry over this time.

Lumosa Therapeutics has approximately 21-50 employees. The company continues to grow its workforce to support its business operations and expansion.